Prostate Cancer P D:前列腺癌分子变异和相关MRI特性分析

2017-08-10 AlexYang MedSci原创

多参数的核磁共振成像(mpMRI)在前列腺癌(PCa)中的使用频率正在增加。最近的研究鉴定了不同的PCa分子亚类,且具有复发性基因组变异特征。然而,在前列腺癌中的分子变异与mpMRI相关的特性仍旧是未知的。基于该背景,最近,有研究人员调查了前列腺癌中复发性分子变异与mpMRI特性的相关关系。研究中,研究恩怨62个大于0.5厘米的前列腺癌瘤进行了手术前的mpMRI,并对囊肿进行了ERG重排、PTEN

多参数的核磁共振成像(mpMRI)在前列腺癌(PCa)中的使用频率正在增加。最近的研究鉴定了不同的PCa分子亚类,且具有复发性基因组变异特征。然而,在前列腺癌中的分子变异与mpMRI相关的特性仍旧是未知的。基于该背景,最近,有研究人员调查了前列腺癌中复发性分子变异与mpMRI特性的相关关系。

研究中,研究恩怨62个大于0.5厘米的前列腺癌瘤进行了手术前的mpMRI,并对囊肿进行了ERG重排、PTEN缺失、SPINK1超表达、SPOP突变和CHD1缺失评估。每一个前列腺癌病灶都与相关的mpMRI位置进行匹配,并根据PI-RADSv2模块,通过单观测器进行病变部位评分。

研究发现,在62个囊肿中,22个(35.5%)表现为ETG阳性,6(9.7%)个表现为SPINK1超表达,6个(9.7%)表现为SPOP突变,4个(6.5%)表现为CHD1缺失,1个(1.6%)表现为PTEN缺失。并且所有具有CHD1缺失的囊肿在mpMRI中不是可视化的,但是所有具有SPINK1超表达的囊肿在mpMRI中是可视化的,尽管相关性并不显著(P=0.06)。另外,分子变异与PI-RADS得分严重度没有显著的相关性(P>0.05)。

最后,研究人员表示,该调查是首次阐释分子变异与前列腺癌囊肿mpMRI特性相关性的文章。该研究也可以为未来的研究作为假设发展,从而严格地评估特异的PCa分子亚类与成像特性的关系,从而进一步扩展MRI在前列腺癌鉴定中的作用。

原始出处:

D Lee, J Fontugne, N Gumpeni et al. Molecular alterations in prostate cancer and association with MRI features. Prostate Cancer P D. 01 August 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791520, encodeId=e1361e915208e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 28 13:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233102, encodeId=fd84233102b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM66WRRAmeqIVSnDN88DpaJfEWzRZxg4yBbiaBmMRwcvViaA2C0sE0Ts3Lic24JSSI4YffujDtpnm0GTHpuiao9TytmNArrcYESnSXY/0, createdBy=7938104912, createdName=jacob9231, createdTime=Sun Aug 13 08:52:40 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342420, encodeId=a2b613424208a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364220, encodeId=24a9136422048, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601909, encodeId=810e16019095c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791520, encodeId=e1361e915208e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 28 13:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233102, encodeId=fd84233102b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM66WRRAmeqIVSnDN88DpaJfEWzRZxg4yBbiaBmMRwcvViaA2C0sE0Ts3Lic24JSSI4YffujDtpnm0GTHpuiao9TytmNArrcYESnSXY/0, createdBy=7938104912, createdName=jacob9231, createdTime=Sun Aug 13 08:52:40 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342420, encodeId=a2b613424208a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364220, encodeId=24a9136422048, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601909, encodeId=810e16019095c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-13 jacob9231

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1791520, encodeId=e1361e915208e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 28 13:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233102, encodeId=fd84233102b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM66WRRAmeqIVSnDN88DpaJfEWzRZxg4yBbiaBmMRwcvViaA2C0sE0Ts3Lic24JSSI4YffujDtpnm0GTHpuiao9TytmNArrcYESnSXY/0, createdBy=7938104912, createdName=jacob9231, createdTime=Sun Aug 13 08:52:40 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342420, encodeId=a2b613424208a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364220, encodeId=24a9136422048, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601909, encodeId=810e16019095c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791520, encodeId=e1361e915208e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 28 13:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233102, encodeId=fd84233102b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM66WRRAmeqIVSnDN88DpaJfEWzRZxg4yBbiaBmMRwcvViaA2C0sE0Ts3Lic24JSSI4YffujDtpnm0GTHpuiao9TytmNArrcYESnSXY/0, createdBy=7938104912, createdName=jacob9231, createdTime=Sun Aug 13 08:52:40 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342420, encodeId=a2b613424208a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364220, encodeId=24a9136422048, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601909, encodeId=810e16019095c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-12 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791520, encodeId=e1361e915208e, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Feb 28 13:22:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233102, encodeId=fd84233102b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM66WRRAmeqIVSnDN88DpaJfEWzRZxg4yBbiaBmMRwcvViaA2C0sE0Ts3Lic24JSSI4YffujDtpnm0GTHpuiao9TytmNArrcYESnSXY/0, createdBy=7938104912, createdName=jacob9231, createdTime=Sun Aug 13 08:52:40 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342420, encodeId=a2b613424208a, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364220, encodeId=24a9136422048, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601909, encodeId=810e16019095c, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sat Aug 12 12:22:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-12 sunylz

相关资讯

Prostate Cancer Prostatic Dis:前列腺癌相关基因分子改变之后MRI有何变化?

多参数磁共振成像(mpMRI)已越来越多地用于前列腺癌(PCa)的检测。最近的研究发现了PCa复发基因的不同分子亚群的改变。然而,在PCa中的分子改变与mpMRI所呈现的特性之间的关联是未知的。本研究的目的是探讨PCa中复发性分子的改变与mpMRI特征之间的关系。

J Clin Oncol:卡巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣?

前列腺癌占到男性肿瘤的15%,且转移性去势抵抗性前列腺癌(mCRPC)是主要死因。随着越来越多的新型药物及治疗方法批准用于mCRPC的治疗,深入探索治疗顺序及药物间的联合越来越重要。卡巴他赛是二代紫杉烷类化疗药物,既往临床研究已经证实其作为二线化疗方案可以延长mCRPC患者的OS,但是其作为一线化疗方案对比多西他赛是否能够使mCRPC患者进一步获益?7月28日,《JOURNAL OF CLINIC

Prostate:表观遗传风险评分提高了对前列腺癌的风险评估。

侵袭性前列腺癌(PCA)的早期检测对患者的治疗效果仍然是至关重要的。然而,现有的前列腺癌筛查因其较高的过度诊断和过度治疗率而存在争议。为了更好地兼顾双方,在诊断时开发出更有效地评估疾病严重程度的方法是十分必要的。

Cancer:在比利时,机器人协助的腹腔镜前列腺切除术病人的当前趋势

在上一个10年中,研究人员在高级中心中的根治性前列腺切除术系列中发现了反向阶段迁移。然而,是否在只有机器人实践以及非转诊中心中观察到相似的趋势还不清楚。最近,有研究人员调查了比利时机器人协助的腹腔镜前列腺切除术病人(RALP)的临床和病理趋势情况,并进行了一个前瞻性的为期6年的分析。研究人员建立了一个前瞻性的、多中心的数据库,并召集了在2010年到2015年,比利时国家中连续经历RALP的病人参与

Eur J Radiol:玩转DCE MRI之半定量动态增强MRI在评估前列腺癌特点和分级的价值!

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。2012年我国肿瘤登记地区前列腺癌发病率为9.92/10万,列男性恶性肿瘤发病率的第6位。发病年龄在55岁前处于较低水平,55岁后逐渐升高,

Int J Mol Sci:miRNA或可更好的预测前列腺癌的发生

前列腺癌是男性中最常见的非皮肤癌,但是目前的诊断方法尚不充分,需要寻找更可靠的诊断标记,而miRNAs或可弥补这一缺陷。这些miRNA分子可在转录水平上影响蛋白质表达,调控重要的细胞通路,其功能失调能够引发致瘤作用导致癌症的发生。在本研究中,研究共纳入了诊断初期和治疗前的28位前列腺癌患者以及12名健康对照者,收集其血液样本并提取其中的miRNAs。使用高通量测序来鉴定可用作前列腺癌诊断生物标志物